相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
Sarah Knispel et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
Shumei Kato et al.
ONCOLOGIST (2018)
Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)
Antoni Xavier Torres-Collado et al.
CANCERS (2018)
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Gustavo S. Fernandes et al.
BMC CANCER (2018)
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma
Daniel L. Faden et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma
Daniel L. Faden et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Clinical impact of extensive molecular profiling in advanced cancer patients
Sophie Cousin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Ameloblastoma: a clinical review and trends in management
Andrew C. McClary et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2016)
BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response
Serena Tan et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2016)
Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma
Frederic J. Kaye et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Identification of recurrent SMO and BRAF mutations in ameloblastomas
Robert T. Sweeney et al.
NATURE GENETICS (2014)
分享论文
